We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Stay up to date on the topics that matter to you

Molly Coddington profile page

Senior Writer and Newsroom Team Lead

at Technology Networks

Molly reports on various scientific topics, covering the latest breaking news and writing long-form pieces. In 2020, she created the Teach Me in 10 video series, where weekly guests discuss and teach a scientific concept in less than 10 minutes. Before joining Technology Networks in 2019, Molly worked as a clinical research associate in the NHS and as a freelance science writer. She has a first-class honors degree in neuroscience from the University of Leeds and received a Partnership Award for her efforts in science communication.

Education

University of Leeds

Awards & Certifications

Georgina Henry Award for Digital Innovation Nominee

Lord Laidlaw Scholarship Recipient, University of Leeds

Partnership Award, University of Leeds

Accreditations

Neuroscience, BSc (Hons) recognised by the University of Leeds

Areas of Expertise

Got a Question for Molly Coddington?

Get in touch using the contact form linked here and we’ll get back to you shortly.

Published Content

Total: 902

Tiny fragments of plastic on a person's hand.

Microplastics Detected in Human Penis for the First Time

Tiny fragments of plastic waste have been detected in human penile tissue for the first time, raising new questions about how environmental pollutants may affect sexual and reproductive health.

A person laying down.

Industry Insight

What FDA Approval of MDMA Could Mean for the Future of Psychedelic Therapy

To learn more about the FDA's pending decision on MDMA-assisted therapy for PTSD, Technology Networks interviewed Dr. Sam Clark, CEO of Terran Biosciences, who leads one of the industry’s largest psychedelic development programs.

An abstract image of the brain.

Brain Imaging Identifies Six Subtypes of Depression

Stanford Medicine scientists have identified six “biotypes” of depression by using machine learning to group depressed patients’ brain images.

A puzzle that spells the word autism.

Brain Cell Overgrowth Before Birth Associated With Autism Severity

Brain organoids derived from toddlers with autism spectrum disorder suggest that subtypes of the condition may have in utero origins. That's according to a new study from researchers at the University of California San Diego, led by Dr. Alysson R. Muotri.

John Lesica, president, chromatography and mass spectrometry at Thermo Fisher Scientific.

Industry Insight

Optimizing Analytical Tools To Accelerate Translational Research

John Lesica, president of chromatography and mass spectrometry at Thermo Fisher Scientific, joined Technology Networks for an interview at this year's American Society for Mass Spectrometry event.

A green field.

CRISPR-Cas9 Editing in Plants: What's the Latest Research?

In this article, we take a look at the latest advancements in research applying multiplex CRISPR-Cas9 genome editing to plants.

Jose Castro-Perez and Chris Lock.

Industry Insight

Driving Sensitivity and Resilience in Mass Spectrometry at ASMS 2024

Technology Networks joined SCIEX for a discussion about the company’s latest product launches at this year’s ASMS conference.

A mother and her baby.

Digital Babies Created To Simulate the First 180 Days of Life

Whole-body models (WBMs) are computational models that integrate different types of multiomics data such as genomic, metabolic and proteomic insights, and have been created to simulate and study adult physiology and disease. WBMs for newborns, however, are currently lacking – until now.

Omid Farokhzad, chair and CEO at Seer.

Industry Insight

Pushing the Boundaries of Biological Discovery in Proteomics

Dr. Omid Farokhzad, chair and CEO at Seer, discusses how to achieve deep, unbiased and scalable analysis of the proteome at speed at ASMS 2024.

The US FDA.

MDMA Therapy for PTSD Receives “No” Vote From FDA Advisory Committee

A key advisory panel to the US FDA has voted that midomafetamine (MDMA) is not effective nor risk-free for treating PTSD.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter